Volume 27, Issue 3, Pages (March 2015)

Slides:



Advertisements
Similar presentations
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.
Advertisements

Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data  Julia L. Williams, Peter A. Greer,
Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma  Fred C. Lam, Michael B. Yaffe  Cancer.
Cancer: Inappropriate Expression of Stem Cell Programs?
Kristin G. Anderson, Ingunn M. Stromnes, Philip D. Greenberg 
A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors  Rajyalakshmi.
The Functional Impact of Alternative Splicing in Cancer
Targeting Aneuploidy for Cancer Therapy
Landscape overview of GENIE dataset.
Carlos L. Arteaga, Jeffrey A. Engelman  Cancer Cell 
Kenneth L. Scott, Scott Powers  Cancer Cell 
Spatiotemporal Evolution of the Primary Glioblastoma Genome
PI3K Regulatory Subunits Lose Control in Cancer
Christian Grommes, Anas Younes  Cancer Cell 
Volume 6, Issue 5, Pages e5 (May 2018)
Total-Genome Analysis of BRCA1/2-Related Invasive Carcinomas of the Breast Identifies Tumor Stroma as Potential Landscaper for Neoplastic Initiation 
WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.
Communication in Drug Development: “Translating” Scientific Discovery
From Prescription to Transcription: Genome Sequence as Drug Target
Volume 45, Issue 5, Pages (November 2016)
New Views into the Genetic Landscape of Metastatic Breast Cancer
Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation 
Volume 29, Issue 5, Pages (May 2016)
The Amazing and Deadly Glioma Race
Michael S. Glickman, Charles L. Sawyers  Cell 
Attention-Induced Variance and Noise Correlation Reduction in Macaque V1 Is Mediated by NMDA Receptors  Jose L. Herrero, Marc A. Gieselmann, Mehdi Sanayei,
Implementing Genome-Driven Oncology
Transcriptional Addiction in Cancer
Volume 23, Issue 4, Pages (April 2018)
The Genetic Basis for Cancer Treatment Decisions
Volume 31, Issue 2, Pages (February 2017)
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Lung Cancer: A Wily Genetic Opponent
Michael D. Brooks, Monika L. Burness, Max S. Wicha  Cell Stem Cell 
Volume 9, Issue 3, Pages (March 2006)
Volume 150, Issue 6, Pages (September 2012)
HIV Drug to Aid Melanoma Therapies?
The Many Faces of PPARγ Cell
Volume 18, Issue 1, Pages (January 2017)
Volume 7, Issue 3, Pages (September 2016)
Molecular Therapy - Methods & Clinical Development
Volume 27, Issue 3, Pages (March 2015)
Miquel Duran-Frigola, Patrick Aloy  Chemistry & Biology 
Volume 24, Issue 12, Pages e5 (September 2018)
Volume 155, Issue 4, Pages (November 2013)
Michal Levin, Tamar Hashimshony, Florian Wagner, Itai Yanai 
Volume 24, Issue 7, Pages (August 2018)
Molecular prognostication of liver cancer: End of the beginning
Mapping Cancer Origins
Volume 31, Issue 2, Pages (February 2017)
Principles and Strategies for Developing Network Models in Cancer
Kenneth L. Scott, Scott Powers  Cancer Cell 
Volume 32, Issue 4, Pages e5 (October 2017)
Spatiotemporal Evolution of the Primary Glioblastoma Genome
Volume 22, Issue 3, Pages e4 (September 2017)
Volume 29, Issue 5, Pages (May 2016)
Volume 122, Issue 6, Pages (September 2005)
Samirkumar B. Amin, Roel G.W. Verhaak  Cell Systems 
Volume 5, Issue 1, Pages (January 2019)
Volume 15, Issue 12, Pages (June 2016)
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Volume 167, Issue 2, Pages e9 (October 2016)
Squamous Cell Cancers: A Unified Perspective on Biology and Genetics
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Stephen Bridgett, James Campbell, Christopher J. Lord, Colm J. Ryan 
Matthew R. Roesch, Adam R. Taylor, Geoffrey Schoenbaum  Neuron 
Personalized genomic analyses for cancer mutation discovery and interpretation by Siân Jones, Valsamo Anagnostou, Karli Lytle, Sonya Parpart-Li, Monica.
Molecular characterization of esophagogastric tumors.
Volume 28, Issue 4, Pages e6 (July 2019)
No Driver behind the Wheel? Targeting Transcription in Cancer
Presentation transcript:

Volume 27, Issue 3, Pages 382-396 (March 2015) In Silico Prescription of Anticancer Drugs to Cohorts of 28 Tumor Types Reveals Targeting Opportunities  Carlota Rubio-Perez, David Tamborero, Michael P. Schroeder, Albert A. Antolín, Jordi Deu-Pons, Christian Perez-Llamas, Jordi Mestres, Abel Gonzalez-Perez, Nuria Lopez-Bigas  Cancer Cell  Volume 27, Issue 3, Pages 382-396 (March 2015) DOI: 10.1016/j.ccell.2015.02.007 Copyright © 2015 Elsevier Inc. Terms and Conditions

Cancer Cell 2015 27, 382-396DOI: (10.1016/j.ccell.2015.02.007) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 1 Graphical Summary of the Approach The first step consists of identifying genomic driver events acting in the tumor cohort. Step two involves finding the drugs targeting the driver protein products, and step three uses the generated information to in silico prescribe drugs to patients on the basis of their genomic driver events. This approach, applied to all patients in the cohort, provides the therapeutic landscape of cancer drivers shown in the middle panel. Cancer Cell 2015 27, 382-396DOI: (10.1016/j.ccell.2015.02.007) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 2 The Cancer Drivers Database (A) Table summarizing the number of cohorts and samples analyzed for each tumor type and the number of mutational drivers detected in each. (B) Frequency of somatic mutations of 177 selected mutational drivers of eight cancer-related biological processes. The top panel contains graphs of processes long known to be involved in cancer; the bottom panel is dedicated to regulatory processes only recently linked to tumorigenesis. Colors in row-stacked histogram follow the legend in (A). (C and D) Frequency of alterations in (C) CNA and (D) fusion drivers across the core cohort. (E) Distribution of drivers according to their type of oncogenic alterations. See also Figure S1 and Table S1. Cancer Cell 2015 27, 382-396DOI: (10.1016/j.ccell.2015.02.007) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 3 Ancillary Information in the Cancer Drivers Database (A) Mode of action of mutational driver genes. (B) Major mutational drivers detected in datasets of the core cohort. Each dot represents a gene placed in the y axis according to their median proportion of clonal population containing protein affecting mutations in it. Orange dots show the major drivers in each cancer type. (C) Distribution of the number of altered drivers across all samples of the core cohort (left) and across each of its individual datasets (right). See also Figure S2 and Table S2. Cancer Cell 2015 27, 382-396DOI: (10.1016/j.ccell.2015.02.007) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 4 Drugs Targeting Cancer Drivers (A) Number of driver genes within each unique druggability category. Note that each driver gene is counted only once in this plot and is placed in the category according to the ordered hierarchy. (B) Number of driver genes that are targets of therapeutic agents with the three levels of approval in the clinical practice. (C) Distribution of driver genes susceptible to the three types of targeting strategies with different levels of approval in the clinical practice. (D) Distribution of driver genes, within each targeting strategy, targeted by agents with the three levels of approval in clinical practice. See also Figure S3 and Table S3. Cancer Cell 2015 27, 382-396DOI: (10.1016/j.ccell.2015.02.007) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 5 Therapeutic Landscape of the Core Cohort Sets of patients susceptible of different types of interventions are shown both in their overlaps (A) and as non-overlapping groups following a hierarchy (B) (i.e., each patient is uniquely labeled in one category following the ordered hierarchy). The same classification for full cohort is available in Figure S4A. See also Table S4. Cancer Cell 2015 27, 382-396DOI: (10.1016/j.ccell.2015.02.007) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 6 The Landscape of Targeted Therapies in Patients of the Core Cohort (A) Distribution of patients across tumor types of therapeutic interventions defined in the text (non-overlapping groups as in Figure 4C) in each cohort. (B) Number of patients susceptible of each types of therapeutic intervention (overlapping as in Figure 4B) in each cohort. The bars at the right of the heatmap illustrate the total number of patients benefiting from each type of therapeutic intervention. (C) Distribution of patients susceptible to receive different number of targeted therapeutic agents—based on their altered drivers—in each cohort (left) and across the entire core cohort (right). (Only drivers targeted by FDA-approved agents and agents in clinical trials were considered.) See also Figure S4. Cancer Cell 2015 27, 382-396DOI: (10.1016/j.ccell.2015.02.007) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 7 Examples of Targeted Drivers in the Core Cohort (A) The top 20 genes ranking at the top of the number of patients tractable with FDA-approved targeted agents across the entire core cohort. The heatmap at the left illustrates the numbers of samples with alterations of each gene in each tumor type separately. See Figure S5A for the complete heatmap of the targeted genes. (B) Same as (A) for genes ranking at the top of the number of patients tractable with agents in clinical trials. See Figure S5B for the complete heatmap of the targeted genes. See also Figure S5. Cancer Cell 2015 27, 382-396DOI: (10.1016/j.ccell.2015.02.007) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 8 Mutation Frequency of Cancer Driver Genes that Are Bound by Pre-clinical Ligands or are Potentially Druggable or Biopharmable See also Table S5. Cancer Cell 2015 27, 382-396DOI: (10.1016/j.ccell.2015.02.007) Copyright © 2015 Elsevier Inc. Terms and Conditions